KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Operating Expenses: 2009-2025

Historic Operating Expenses for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Sep 2025 value amounting to $573.0 million.

  • Teva Pharmaceutical Industries' Operating Expenses rose 6.51% to $573.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 billion, marking a year-over-year increase of 4.04%. This contributed to the annual value of $2.2 billion for FY2024, which is 2.08% up from last year.
  • Latest data reveals that Teva Pharmaceutical Industries reported Operating Expenses of $573.0 million as of Q3 2025, which was up 4.37% from $549.0 million recorded in Q2 2025.
  • Teva Pharmaceutical Industries' 5-year Operating Expenses high stood at $573.0 million for Q3 2025, and its period low was $458.0 million during Q3 2022.
  • Over the past 3 years, Teva Pharmaceutical Industries' median Operating Expenses value was $544.0 million (recorded in 2025), while the average stood at $540.2 million.
  • As far as peak fluctuations go, Teva Pharmaceutical Industries' Operating Expenses decreased by 15.97% in 2021, and later climbed by 13.76% in 2023.
  • Over the past 5 years, Teva Pharmaceutical Industries' Operating Expenses (Quarterly) stood at $521.0 million in 2021, then declined by 4.41% to $498.0 million in 2022, then climbed by 4.22% to $519.0 million in 2023, then increased by 5.78% to $549.0 million in 2024, then climbed by 6.51% to $573.0 million in 2025.
  • Its Operating Expenses stands at $573.0 million for Q3 2025, versus $549.0 million for Q2 2025 and $544.0 million for Q1 2025.